OSI-774 (Erlotinib, Tarceva) in Elderly Patients
The purpose of this research study is to determine if OSI-774 (Tarceva) is effective in the treatment of non-small cell lung cancer and to further study its side effects. The investigators would also like to estimate disease-related symptom improvement rates using a questionnaire.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
The study team can explain what participation involves.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Dec 30, 2019 · Source: ClinicalTrials.gov
Ask the study team to confirm whether enrollment is open.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Montefiore Medical Center
- Interventions being studied
- Drug: Tarceva
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
Patients must have confirmed non-small cell lung cancer. Age \> 65 years Patients must have adequate organ and marrow function
Patients who have had prior chemotherapy will be excluded. Patients may not be receiving any other investigational agents.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Beth Israel Medical CenterNew York, New York
- New York UniversityNew York, New York
- Albert Einstein Cancer CenterThe Bronx, New York
- Montefiore Medical Center-The Bronx, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 30, 2019. Always confirm current availability with the study team.